Ignite Creation Date:
2024-05-06 @ 2:02 AM
Last Modification Date:
2024-10-26 @ 11:12 AM
Study NCT ID:
NCT01951482
Status:
UNKNOWN
Last Update Posted:
2017-10-26
First Post:
2013-09-16
Brief Title:
PemetrexedCisplatin With or Without Bevacizumab in Brain Metastases From Non Squamous Non-small Cell Lung Cancer
Sponsor:
Sun Yat-sen University
Organization:
Sun Yat-sen University
Study Overview
Official Title:
Multicenter Phase II Study of PemetrexedCisplatin With or Without Bevacizumab in Patients With Brain Metastases From Non Squamous Non-small Cell Lung Cancer Harboring EGFR Wild Type
Status:
UNKNOWN
Status Verified Date:
2017-10
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a multi-center phase II randomized controlled study to assess the efficacy of Pemetrexedcisplatin with or without Bevacizumab on patients with brain metastasis from non-small cell lung cancerNSCLC harboring EGFR wild type by intracranial PFSiPFSalso PFS DCR and OSThe side effect is evaluated as well
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None